<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Frontiers Media SA</publisher>
				<availability status="unknown"><p>Copyright Frontiers Media SA</p>
				</availability>
				<date type="published" when="2012-02-20">20 February 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rosaria</forename><surname>Santangelo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Microbiology</orgName>
								<orgName type="institution">Catholic University School of Medicine</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cesare</forename><surname>Mancuso</surname></persName>
							<email>cmancuso@rm.unicatt.it</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pharmacology</orgName>
								<orgName type="institution">Catholic University School of Medicine</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simona</forename><surname>Marchetti</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Microbiology</orgName>
								<orgName type="institution">Catholic University School of Medicine</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Enrico</forename><surname>Di Stasio</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovambattista</forename><surname>Pani</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute of General Pathology</orgName>
								<orgName type="institution">Catholic University School of Medicine</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><surname>Fadda</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Microbiology</orgName>
								<orgName type="institution">Catholic University School of Medicine</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">University of Rochester</orgName>
								<address>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Pavel Anzenbacher</orgName>
								<orgName type="institution">University of Eastern Finland</orgName>
								<address>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">Palacky University</orgName>
								<address>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">School of Medicine and Dentistry</orgName>
								<orgName type="institution">University of Rochester</orgName>
								<address>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Institute of Pharmacology</orgName>
								<orgName type="department" key="dep2">Catholic University School of Medicine</orgName>
								<address>
									<addrLine>Largo Francesco Vito, 1</addrLine>
									<postCode>00168</postCode>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Frontiers in Pharmacology</title>
						<title level="j" type="abbrev">Front. Pharmacol.</title>
						<idno type="eISSN">1663-9812</idno>
						<imprint>
							<publisher>Frontiers Media SA</publisher>
							<biblScope unit="volume">3</biblScope>
							<date type="published" when="2012-02-20">20 February 2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.3389/fphar.2012.00036</idno>
					<idno type="PMID">22408623</idno>
					<idno type="PMCID">PMC3297833</idno>
					<ptr type="open-access" target="https://www.frontiersin.org/articles/10.3389/fphar.2012.00036/pdf" />
					<note type="submission">Received: 09 January 2012; paper pending</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:06+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>bilirubin</term>
					<term>biliverdin reductase</term>
					<term>enterovirus</term>
					<term>heme oxygenase</term>
					<term>herpes simplex virus</term>
					<term>nitric oxide</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Bilirubin-IX-alpha (BR) is the final product of heme metabolism through the heme oxygenase/biliverdin reductase (HO/BVR) system. Previous papers reported on the microbicidal effects of the HO by-products biliverdin-IX-alpha, carbon monoxide and iron, through either direct or indirect mechanisms. In this paper the evidence of a virucidal effect of BR against human herpes simplex virus type 1 (HSV-1) and the enterovirus EV71 was provided. Bilirubin-IX-alpha, at concentrations 1-10 μM, close to those found in blood and tissues, significantly reduced HSV-1 and EV71 replication in Hep-2 and Vero cell lines, respectively. Bilirubin-IX-alpha inhibited viral infection of Hep-2 and Vero cells when given 2 h before, concomitantly and 2 h after viral infection. Furthermore, BR retained its antiviral activity even complexed with a saturating concentration of human serum-albumin. Moreover, 10 μM BR increased the formation of nitric oxide and the phosphorylation of c-Jun N-terminal kinase in Vero and Hep-2 cell lines, respectively, thus implying a role of these two pathways in the mechanism of antiviral activity of the bile pigment. In conclusion, these results support the antiviral effect of BR against HSV-1 and enterovirus in vitro, and put the basis for further basic and clinical studies to understand the real role of BR as an endogenous antiviral molecule.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>The heme oxygenase/biliverdin reductase (HO/BVR) axis is the main metabolic pathway by which heme is degraded. The combined action of these enzymes converts heme into ferrous iron (FeII), carbon monoxide (CO), and biliverdin-IX-alpha (BV) which is the precursor of bilirubin-IX-alpha (BR; <ref type="bibr" target="#b25">Maines, 1997;</ref><ref type="bibr" target="#b27">Mancuso and Barone, 2009)</ref>. For several years, the by-products of the HO/BVR axis were considered mere waste products, but over the past two decades, a number of investigators have focused their attention on both HO/BVR and their products in an attempt to elucidate their true biological functions. <ref type="bibr" target="#b41">Stocker et al. (1987b)</ref> described the antioxidant properties of BR, and 6 years later <ref type="bibr" target="#b44">Verma et al. (1993)</ref> proposed a role for CO as an endogenous neuromodulator. These observations were followed by numerous papers demonstrating CO's important role as a regulator of synaptic transmission, cardiac function, and vessel tone <ref type="bibr" target="#b47">(Wu and Wang, 2005)</ref>. Bilirubin-IX-alpha helps maintain the cell's redox equilibrium by activating important pro-survival signaling pathways, such as those involving the proto-oncogene Akt or the mitogenactivated protein kinase family (MAPK), and by scavenging reactive oxygen and nitrogen species <ref type="bibr">(ROS and RNS, respectively;</ref><ref type="bibr" target="#b41">Stocker et al., 1987b;</ref><ref type="bibr" target="#b31">Minetti et al., 1998;</ref><ref type="bibr" target="#b20">Kaur et al., 2003;</ref><ref type="bibr" target="#b29">Mancuso et al., 2006b</ref><ref type="bibr" target="#b30">Mancuso et al., , 2008</ref>. These findings suggest that up-regulation of the HO/BVR axis is a useful mechanism for improving cells' responses to stress, and substances known to increase HO activity in vitro are being explored as potential drugs for the treatment of free radical-induced diseases <ref type="bibr" target="#b27">(Mancuso and Barone, 2009)</ref>. In addition, the up-regulation of HO was shown to play an important role against bacterial and viral infections. The overexpression of the inducible isoform of HO (HO-1) displayed a significant antiviral activity against enterovirus and hepatitis viruses <ref type="bibr" target="#b48">(Zhu et al., 2010;</ref><ref type="bibr" target="#b43">Tung et al., 2011)</ref>. With regard to the by-products of the HO system involved in this antiviral activity, BV was shown to interfere with human hepatitis C virus (HCV) and human herpes virus (HHV)-6 replication as well as to reduce the cytopathic effect of human immunodeficiency type 1 virus (HIV) in Huh or MT-4 cells <ref type="bibr" target="#b32">(Mori et al., 1991;</ref><ref type="bibr" target="#b33">Nakagami et al., 1992;</ref><ref type="bibr" target="#b23">Lehmann et al., 2010;</ref><ref type="bibr" target="#b48">Zhu et al., 2010)</ref>. In addition, CO inhibited the growth of enterovirus, E. coli, P. aeruginosa as well as S. aureus <ref type="bibr" target="#b36">(Nobre et al., 2007;</ref><ref type="bibr" target="#b43">Tung et al., 2011;</ref><ref type="bibr" target="#b10">Desmard et al., 2012)</ref> and iron almost completely decreased HCV core mRNA and protein <ref type="bibr" target="#b17">(Hou et al., 2009)</ref>. Taken together these results underlined a major role for HO in antiviral and antibacterial defense. That said, it is noteworthy to mention that no data are available to date about the potential antiviral activity of BR produced by BVR. As mentioned before, BR was shown to serve as an efficient scavenger for ROS which, in turn, are currently viewed as effectors of the antimicrobial activity of the immune response <ref type="bibr" target="#b5">(Bogdan et al., 2000;</ref><ref type="bibr" target="#b11">Fang, 2004;</ref><ref type="bibr" target="#b13">Fialkow et al., 2007)</ref>, therefore a direct antiviral role for BR is unlikely. On the other hand, recent findings demonstrated alternative mechanisms for the cytoprotective activity of BR, including the stimulation of nitric oxide (NO) release and the modulation of the MAPK system in pheochromocytoma cells and primary cultures of rat cerebellar granules <ref type="bibr" target="#b30">(Mancuso et al., 2008)</ref>. NO plays an important role in the antiviral defense <ref type="bibr" target="#b8">(Croen, 1993;</ref><ref type="bibr" target="#b0">Akaike and Maeda, 2000)</ref> and it is also an intermediate in the bactericidal activity of certain drugs <ref type="bibr" target="#b42">(Timmins et al., 2004;</ref><ref type="bibr" target="#b22">Koide et al., 2009)</ref>. Moreover, the upregulation of specific MAPK, such as the c-Jun N-terminal kinase (JNK), was shown to increase the cytoprotective defense against viruses <ref type="bibr" target="#b18">(Hrincius et al., 2010)</ref>.</p><p>The aim of this work was to explore the antiviral activity of BR in vitro and the plausible intracellular systems involved in this protective effect. Since intracellular BR exists in the free form whereas in the bloodstream the bile pigment is bound to human serumalbumin (HSA), the antiviral activity of both BR and BR-HSA were studied. The viral species against which BR and BR-HSA were tested are the human herpes simplex type 1 virus (HSV-1), a DNA virus which belong to the Herpesviridae family, and enterovirus 71 (EV71) which belong to the Picornaviridae family (RNA viruses). Both these viruses are responsible for important acute and chronic diseases in humans.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CHEMICALS AND ANTIBODIES</head><p>All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. Bilirubin-IX-alpha (Frontier Scientific, Carnforth, Lancashire, UK) was dissolved in sodium hydroxide (0.1 M) at a concentration of 10 mM and further diluted in double-distilled water. Bilirubin-IX-alpha solution was freshly prepared before each experiment and protected from light. The formation of the BR-HSA complex, at saturating concentrations of the protein, was allowed by incubating BR and HSA for 10 min at 37˚C in the dark at a ratio up to 1:2 <ref type="bibr" target="#b28">(Mancuso et al., 2006a)</ref>. The fluorescent cell-permeant dye 4-amino-5methylamino-2 ,7 -difluorofluorescein (DAF-FM) diacetate was purchased from Molecular Probes (Invitrogen Carlsbad, CA, USA) and the JNK inhibitor SP600125 was from Assay Design (Enzo Life Sciences International, Inc., Plymouth Meeting, PA, USA). Anti-pJNK Thr183/Tyr185, antibody was purchased from Cell Signaling, (Danvers, MA, USA) and the anti-α-tubulin rabbit monoclonal antibody was from Thermo Scientific (Rockford, IL, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CELL CULTURE AND VIRUS PROPAGATION</head><p>The human laryngeal carcinoma cell line (Hep-2) and African green monkey kidney epithelial cells line (Vero) were maintained in Minimum-Essential-Medium (MEM) additioned with 10% fetal calf serum (FCS), glutamine (200 mM), penicillin (100 U/ml) and streptomycin (100 μg/ml). Human herpes simplex virus type 1 (KOS strain) and EV71 were purchased from the ATCC (Milan, Italy) and propagated and titrated in Hep-2 and Vero cells, respectively. The virus titre for both HSV-1 and EV71 was calculated by the plaque assay <ref type="bibr" target="#b38">(Saijets et al., 2003;</ref><ref type="bibr" target="#b19">Hung et al., 2010)</ref>.</p><p>The day before the experiment, 1 × 10 5 Hep-2 or Vero cells were seeded in 24-multiwell plates at a density of 400 cells/mm 2 . After overnight incubation, cells were treated with HSV-1 or EV71 alone or in the presence of test substances as described in Protocols 1-4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>STUDY DESIGN</head><p>In order to mimic the different conditions during which BR could interfere with viral infectivity, four different protocols were designed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 1</head><p>Hep-2 and Vero cells were pre-incubated with BR (1-10 μM) for 2 h. At the end of incubation, the BR-containing medium was discarded, replaced with fresh medium and the cells infected with HSV-1 and EV71. After 2 h, the inocula were removed and the cells incubated in fresh culture medium for 24-48 h. These time points were selected considering the replication cycles of both HSV-1 and enterovirus which are 10-20 h.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 2</head><p>Herpes simplex virus type 1 and EV71 were pre-incubated with BR (1-10 μM) alone or complexed with saturating HSA (20 μM) for 1 h and then transferred to Hep-2 and Vero monolayers for the infection. After 2 h, the inocula were removed and the cells incubated in fresh culture medium for 24-48 h. The effect of HSA per se on viral replication was also evaluated by incubating either HSV-1 or EV71 with 20 μM HSA and then transferring the inocula to Hep-2 and Vero cells as described above.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 3</head><p>Hep-2 and Vero cells were exposed to BR (1-10 μM) alone or complexed with saturating HSA (20 μM) and concomitantly infected with HSV-1 and EV71 for 2 h. At the end of incubation, the inocula were removed and the cells incubated in fresh culture medium for 24-48 h. The antiviral effect of HSA per se was also evaluated by infecting Hep-2 and Vero cells with either HSV-1 or EV71 in the presence of 20 μM HSA as described above.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 4</head><p>After 2 h of infection with HSV-1 and EV71, the inocula were removed and Hep-2 and Vero monolayers treated with BR (1-10 μM) for further 2 h. At the end of incubation the BR-containing medium was discarded and the cells incubated in fresh culture medium for 24-48 h.</p><p>In preliminary experiments, both Hep-2 and Vero cells were incubated with 10-100 μM NaOH for 2 h and then incubated with fresh medium for 24-48 h to evaluate whether or not this substance affected viral infectivity.</p><p>In selected experiments, performed following protocols 1 and 3, Hep-2 and Vero cells were pre-incubated with the NO synthase (NOS) inhibitor L-NG-monomethyl arginine citrate (L-NMMA, 1 mM) for 1 h and further for 2 h in the presence of BR (10 μM) or BR (10 μM)-HSA (20 μM).</p><p>The number of infected cells were calculated by immunofluorescence as described below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>QUANTIFICATION OF INDIVIDUAL INFECTED CELLS</head><p>At the end of the 24 or 48-h incubation, cells were washed with PBS to remove residual culture medium, gently scraped and counted. Twenty-five thousand infected cells were seeded on single slide (four slides for each well) and incubated with anti HSV-1 monoclonal antibody (Imagen Herpes simplex virus direct IF test, Dako Cytomation, UK) or Pan-enterovirus antibody blend (PAN ENTERO BLEND, Light Diagnostics, Temecula, CA, USA) according to the manufacturers' instructions. Immunofluorescence is a simple and reliable method to assess viral infection and is routinely used to estimate either herpesvirus or enterovirus infectivity <ref type="bibr" target="#b21">(Klespies et al., 1996;</ref><ref type="bibr" target="#b38">Saijets et al., 2003;</ref><ref type="bibr" target="#b7">Copeland et al., 2009;</ref><ref type="bibr" target="#b37">Prichard et al., 2009)</ref>. Both total cells and immunofluorescence-positive cells in each sample were counted in at least five microscopy fields (120-160 total cells and ∼5-140 positive cells per field) by two independent blinded investigators and this latter expressed as percentage respect to total cells. The inter-investigator variability rate of cell count was less than 10%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MEASUREMENT OF NO</head><p>Intracellular NO was detected in Vero cells treated for 2 h with BR (1-10 μM) in 0% FCS MEM by using the fluorescent probe DAF-FM-DA as previously described <ref type="bibr" target="#b30">(Mancuso et al., 2008)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>WESTERN BLOT ASSAY</head><p>Confluent Hep-2 and Vero cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, leupeptin, and pepstatin, 1 mM sodium orthovanadate) containing 1% Triton X-100 and 0.1% SDS; lysates were cleared by centrifugation, and equal amounts of protein (40 μg) for each sample were subjected to SDS-PAGE on 10% gel. Western blot analysis was performed as previously described <ref type="bibr" target="#b30">(Mancuso et al., 2008)</ref> by using primary antibodies (see above) diluted 1:1000 and HRP-conjugated secondary antibodies as appropriate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>STATISTICAL ANALYSIS</head><p>Data are expressed as mean ± SEM of (N) individual samples per group. Statistical analysis was performed using ANOVA combined with Dunnet's or two-tailed Student's t -tests for comparison within the same group or two groups, respectively. Differences were considered significant at P &lt; 0.05. The maximal inhibitory activity values were calculated and confirmed by nonlinear regression analysis using a Prism 4.0 software (GraphPad Software).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EFFECTS OF BR OR BR-HSA ON HSV-1 AND EV71 INFECTIVITY</head><p>The first step was to titrate both HSV-1 and EV71 by the plaque assay. The titer for HSV-1 was calculated to be 1.3 × 10 7 plaque forming unit (PFU)/ml whereas for EV71 was 1 × 10 9 PFU/ml. At these titers both HSV-1 and EV71 completely detached the Hep-2 and Vero cell monolayers as early as 24 from infection and this did not allow us to carry out any experiment to prove the possible protective effect of 1-10 μM BR. For this reason, in all the experimental protocols described below, cells were infected with either HSV-1 or EV71 at the titer 1 × 10 5 PFU.</p><p>In preliminary experiments, the unspecific effects of NaOH, the vehicle for BR, on viral replication was studied. Sodium hydroxide in the range 10-100 μM (i.e., the concentrations in 1-10 μM BR) did not have any significant effect on HSV-1 or EV71 infectivity at 24-48 h of incubation (data not shown).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 1</head><p>As shown in <ref type="figure">Figure 1</ref>, Hep-2 and Vero cells pre-incubated with BR (1-10 μM) for 2 h and then infected with HSV-1 and EV71, were markedly resistant to the lethal effect of both the viruses and the percentage of infected cells were significantly reduced both at 24 and 48 h after infection <ref type="figure">(Figure 1)</ref>. However, in this experimental setting BR was slightly more efficacious against HSV-1 than EV71 at 48 h from infection (mean maximal inhibitory activity 95 and 83%, respectively) whereas the efficacy at 24 h was comparable. It is noteworthy to mention that BR displayed a greater potency in inhibiting both HSV-1 and EV71 infectivity at 24 h than at 48 h from the infection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 2</head><p>When HSV-1 and EV71 were pre-incubated with BR (1-10 μM) alone or complexed with HSA (20 μM) for 2 h and then transferred FIGURE 1 | Effect of bilirubin (BR) on herpes simplex virus type 1 (HSV-1) and enterovirus EV71 replication. Hep-2 (A) and Vero (B) cells were pre-incubated with BR (1-10 μM) for 2 h. At the end of incubation, BR was removed and Hep-2 and Vero cells infected with HSV-1 and EV71, respectively, both at the titer 1 × 10 5 PFU. After 2 h, the inocula were removed and the cells incubated in culture medium for 24 (white columns) or 48 h (black columns). Data are expressed as the percentage of infected cells, mean ± SEM of six individual samples per group. *P &lt; 0.05 and **P &lt; 0.01 versus control (C) after 24 h from infection;˚P &lt; 0.05 and˚P &lt; 0.01 versus control after 48 h from infection.</p><p>onto Hep-2 and Vero monolayers, the bile pigment significantly inhibited viral infectivity <ref type="figure">(Figure 2)</ref>. In particular, BR alone exhibited lower efficacy against HSV-1 than EV71 at 24 h from infection (mean maximal inhibitory activity 98 versus 82%, respectively) whereas at 48 h the efficacy was comparable. Furthermore, the complexation with HSA did not alter the efficacy of BR against HSV-1 and EV71 at shorter time from infection whereas reduced the efficacy after 48 h (mean maximal inhibitory activity 54 versus 82%, respectively). Moreover, the complexation with HSA reduced the potency of BR to block HSV-1 replication after 24 h from infection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 3</head><p>In Hep-2 and Vero cells treated with BR (1-10 μM) alone or complexed with HSA (20 μM) and concomitantly infected with HSV-1 FIGURE 2 | Direct effect of bilirubin (BR) and albumin-bound bilirubin (BR-HSA) on herpes simplex virus type 1 (HSV-1) and enterovirus EV71 and how this affects viral replication. Both HSV-1 and EV71 (1 × 10 5 PFU) were pre-incubated with BR (1-10 μM) alone or complexed with saturating HSA (20 μM) for 1 h and then transferred to Hep-2 (A) and Vero (B) cell monolayers for the infection. After 2 h, the inocula were removed and the cells incubated in culture medium for 24 h (white and dashed columns) or 48 h (black and dotted columns). Both dashed and dotted columns refer to HSA treatment as described in the Section "Materials and Methods." Data are expressed as the percentage of infected cells, mean ± SEM of six individual samples per group. *P &lt; 0.05 versus control (C) after 24 h from infection; ** or † P &lt; 0.01 versus respective controls after 24 h from infection;˚or # P &lt; 0.05 and˚˚or ## P &lt; 0.01 versus respective controls after 48 h from infection.</p><p>and EV71, the linear tetrapyrrole significantly modified viral infectivity <ref type="figure">(Figure 3)</ref>. In details, BR alone showed a comparable efficacy against HSV-1 and EV71 at both 24 and 48 h. The complexation with HSA only partially confirmed this trend, since BR exhibited similar efficacy against HSV-1 and EV71 at 24 h, but a lower efficacy at 48 h of incubation (mean maximal inhibitory activity 62 and 82%, respectively). Similarly to Protocol 2, the complexation with HSA reduced the potency of BR to block HSV-1 replication after 24 h from infection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol 4</head><p>When given after viral infection, BR (1-10 μM) significantly reduced HSV-1 virulence only within the first 24 h from the infection, whereas after 48 h only the higher concentration was FIGURE 3 | Effect of bilirubin (BR) and albumin-bound bilirubin (BR-HSA) given concurrently with herpes simplex virus type 1 (HSV-1) and enterovirus EV71 and how this affects viral replication. Hep-2 (A) and Vero (B) cells were exposed to BR (1-10 μM) alone or complexed with saturating HSA (20 μM) and concomitantly infected with HSV-1 and EV71 (1 × 10 5 PFU) for 2 h. At the end of incubation the inocula were removed and the cells incubated in culture medium for 24 (white and dashed columns) or 48 h (black and dotted columns). Both dashed and dotted columns refer to HSA treatment as described in the Section "Materials and Methods." Data are expressed as the percentage of infected cells, mean ± SEM of six individual samples per group. *P &lt; 0.05 versus control (C) after 24 h from infection; ** or † P &lt; 0.01 versus respective controls after 24 h from infection;˚or # P &lt; 0.05 and˚˚or ## P &lt; 0.01 versus respective controls after 48 h from infection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Frontiers in Pharmacology | Drug Metabolism and Transport</head><p>active <ref type="figure">(Figure 4)</ref>. Conversely, BR maintained its antiviral action against EV71 at both 24 and 48 h from the infection <ref type="figure">(Figure 4)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRACELLULAR MECHANISMS THROUGH WHICH BR COULD EXERT ITS ANTIVIRAL ACTIVITY</head><p>Bilirubin-IX-alpha (1-10 μM) stimulated the phosphorylation of the member of the MAPK family JNK in Hep-2 and Vero cell lines ( <ref type="figure" target="#fig_0">Figure 5A</ref> and data not shown), but a positive correlation between BR concentrations and JNK phosphorylation was not found. The JNK inhibitor SP600125 (10 μM) partially reversed the BR (10 μM)-induced block of HSV-1 and EV71 replication in Hep-2 and Vero cells at both 24 and 48 h from infection (protocols 1 and 3), but this result only approached statistical significance (data not shown).</p><p>In addition, BR (10 μM) increased the production of NO in Vero cells in a time-dependent manner reaching statistical significance as early as 2 h after the administration <ref type="figure" target="#fig_0">(Figure 5B)</ref>. The involvement of BR-dependent generation of NO in the inhibition FIGURE 4 | Effects of bilirubin (BR) on cell monolayers infected with herpes simplex virus type 1 (HSV-1) and enterovirus EV71. After 2 h of infection with HSV-1 and enterovirus (1 × 10 5 PFU), Hep-2 (A) and Vero (B) cell monolayers were treated with BR (1-10 μM) for further 2 h. At the end of incubation the inocula were removed and the cells incubated in culture medium for 24 (white columns) or 48 h (black columns). Data are expressed as the percentage of infected cells, mean ± SEM of six individual samples per group. *P &lt; 0.05 and **P &lt; 0.01 versus control (C) after 24 h from infection;˚˚P &lt; 0.01 versus control after 48 h from infection. of viral replication was confirmed in specific experiments performed by incubating Hep-2 and Vero cells with L-NMMA (1 mM) 1 h before and then in the presence of BR (10 μM, 2 h) as described in protocol 1. These experiments demonstrated that the inhibition of NOS activity reversed the BR-induced block of viral replication in HSV-1 and EV71 after 24 h and 48 h from infection ( <ref type="figure" target="#fig_1">Figure 6)</ref>. A similar degree of inhibition of viral replication was found when HSV-1 and Vero cells were pre-incubated with L-NMMA for 1 h and then exposed simultaneously to BR alone or complexed with HSA plus HSV-1 or EV71 according to protocol 3 (data not shown). This effect of BR was comparable at both 24 and 48 h from infection (data not shown).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>Over the last years, several studies reported on the microbicidal activity of HO-1 and its by-products. Biliverdin-IX-alpha was shown to inhibit the replication of HCV, HHV-6, and HIV <ref type="bibr" target="#b32">(Mori et al., 1991;</ref><ref type="bibr" target="#b33">Nakagami et al., 1992;</ref><ref type="bibr" target="#b23">Lehmann et al., 2010;</ref><ref type="bibr" target="#b48">Zhu et al., 2010)</ref>, CO reduced the growth of E. coli, P. aeruginosa, and S. aureus <ref type="bibr" target="#b36">(Nobre et al., 2007</ref><ref type="bibr" target="#b35">(Nobre et al., , 2009</ref><ref type="bibr" target="#b9">Davidge et al., 2009;</ref><ref type="bibr" target="#b10">Desmard et al., 2012)</ref> and iron almost completely decreased HCV core mRNA and protein <ref type="bibr" target="#b17">(Hou et al., 2009)</ref>. The results shown in this paper provided original evidence about the antiviral role of BR, the formation of which requires the concerted action of both HO and BVR,   <ref type="figure">1 (HSV-1)</ref> and enterovirus EV71 replication. Hep-2 (A) and Vero (B) cells were pre-incubated with 1 mM L-NMMA for 1 h and then with L-NMMA plus 10 μM BR for further 2 h. At the end of incubation, the medium containing L-NMMA plus BR was removed and Hep-2 and Vero cells infected with HSV-1 and EV71 (1 × 10 5 PFU), respectively. After 2 h, the inocula were removed and the cells incubated in culture medium for 24 (white columns) or 48 h (black columns). Data are expressed as the percentage of infected cells, mean ± SEM of six individual samples per group. **P &lt; 0.01 versus respective controls (C) and˚P &lt; 0.05 and˚P &lt; 0.01 versus 10 μM BR after 24 h (white columns) and 48 h (black columns) from viral infection.</p><p>thus expanding the cytoprotective role of this linear tetrapyrrole. However, in order to appreciate the novelty of our study, some considerations about the pathophysiology of the HO/BVR system are needed.</p><p>Although HO-1 is considered ubiquitous, this isoform is abundantly expressed in liver, spleen, heart, kidney, and selected brain regions and its activity increases greatly under stressful conditions <ref type="bibr" target="#b25">(Maines, 1997)</ref>. On the contrary, the constitutive HO-2 isoform prevails in neurons and testicular germ cells <ref type="bibr" target="#b25">(Maines, 1997)</ref>. Almost all organs retain BVR activity which transforms BV into BR <ref type="bibr" target="#b25">(Maines, 1997</ref><ref type="bibr" target="#b26">(Maines, , 2005</ref>. That said, it is plausible to wonder whether or not the antiviral activity of BV against HHV-6, HIV, or HCV <ref type="bibr" target="#b32">(Mori et al., 1991;</ref><ref type="bibr" target="#b33">Nakagami et al., 1992;</ref><ref type="bibr" target="#b23">Lehmann et al., 2010;</ref><ref type="bibr" target="#b48">Zhu et al., 2010)</ref> should be attributable to its conversion into BR by the MT-4 or Huh cells used in those studies rather than a distinct effect of BV. The lack of inactivation of HHV-6 virions by BV and the consequent reduced antiviral effect lend support to this hypothesis. Another concern raised from the studies by <ref type="bibr" target="#b33">Nakagami et al. (1992)</ref> and <ref type="bibr" target="#b32">Mori et al. (1991)</ref> is related to the concentrations of BV used to inhibit HHV-6 and HIV replication. In these studies the antiviral effect of BV was observed at concentrations ranging from 10 to 66.7 μg/ml, equivalent to ∼17 and 113 μM, respectively, two values much higher than those expected to be produced by the HO activity in humans <ref type="bibr" target="#b6">(Coburn, 1970)</ref>. These potential biases were overcome in our study which demonstrated a direct antiviral effect for BR, the stable end product of heme metabolism, at concentrations from 1 to 10 μM which are very close to those found in human plasma <ref type="bibr" target="#b3">(Berk et al., 1969;</ref><ref type="bibr" target="#b4">Bloomer et al., 1971)</ref> and about 1 order of magnitude lower than those previously used to demonstrate the antiviral effect of BV. From the analysis of the pharmacodynamic data, it emerges a different sensitivity of HSV-1 and EV71 to both free and albumin-bound BR under the various experimental conditions. A careful comparative evaluation of the mechanisms which underlie the ability of BR to inhibit HSV-1 and EV71 infectivity under the conditions which characterized Protocols 1-4, is out of the scope of this paper. However, it is important to highlight that, in this study, both BR and BR-HSA significantly inhibited the infectivity of both HSV-1 and EV71 in all the experimental settings well within the range of physiologic concentrations. A preliminary conclusion drawn from our results was that BR was much more efficacious to inhibit viral infectivity after 24 h from infection and, in particular, when the bile pigment was complexed to HSA.</p><p>The results shown in this study suggest that BR reduce viral replication by acting at several stages. The ability of BR to decrease HSV-1 and EV71 infectivity if pre-incubated with Hep-2 and Vero cells <ref type="figure">(Figure 1)</ref> resembles the pathophysiologic condition in which a virus infects cells endowed with high concentration of BR (e.g., hepatocytes, neurons). This finding is clinically relevant because nervous system and liver are both target organs for HSV-1 and enterovirus. Taking into consideration that there is not a direct clinical evidence of a reduced incidence of viral diseases in subjects affected by conditions characterized by unconjugated hyperbilirubinemia, such as Gilbert's syndrome <ref type="bibr" target="#b14">(Hirschfield and Alexander, 2006)</ref>, we hypothesize a protective role for BR in viral diseases in analogy with the well known protective effect of the bile pigment against respiratory diseases and cardiovascular accidents <ref type="bibr" target="#b45">(Vitek et al., 2002;</ref><ref type="bibr" target="#b16">Horsfall et al., 2011)</ref>. With regard to the inhibition of viral infectivity by both BR and BR-HSA pre-incubated directly with virions <ref type="figure">(Figure 2)</ref>, it recalls the pathophysiologic condition in which a virus comes in contact with BR or BR-HSA in the blood, as during the viremic phase, and then infects tissues. Similarly, both BR and BR-HSA reduced viral replication if given cells concomitantly with HSV-1 and EV71 <ref type="figure">(Figure 3)</ref> and this mimics the pathophysiologic condition in which a virus comes in contact with BR/BR-HSA and cells at the blood/tissue interface. However, it is well known that both herpesviruses and enteroviruses have a short viremic phase since they colonize target organs very fast and, therefore, the potential clinical importance of both these mechanisms is limited to severe diseases characterized by long-lasting veremic phase such as in immunocompromised patients <ref type="bibr" target="#b39">(Stanberry et al., 1994)</ref>. Finally, BR was efficacious in reducing viral infection even when administered to Hep-2 and Vero cells already infected by HSV-1 and EV71, respectively <ref type="figure">(Figure 4)</ref>. This experimental condition reminds of the clinical situation in which jaundice is secondary to a viral infection, such as hepatitis. As a matter of fact, in viral hepatitis unconjugated BR increases when hepatic function decreases under a critical threshold and it is very often accompanied by hypoalbuminemia and hypofibrinogenemia and these alterations represent a life-threatening condition. The possible protective effect of BR at this stage is, therefore, unlikely.</p><p>Overall speaking, the mechanisms involved in the antiviral activity of BR within the cell or at the interface blood/tissue could be related either to the stimulation of intracellular pro-survival pathways, such as the MAPK system, or the production of microbicidal molecules such as NO. The BR-induced stimulation of NO release in Vero cells <ref type="figure" target="#fig_0">(Figure 5)</ref> should be considered as one of the main mechanisms involved in the antiviral effect of the linear tetrapyrrole against both HSV-1 and EV71. The importance of NO to decrease HSV-1 and EV71 infectivity was also corroborated by the evidence that the blockade of NOS, by the inhibitor L-NMMA, reverted the reduction of viral infectivity due to 10 μM BR <ref type="figure" target="#fig_1">(Figure 6</ref>). This result is not surprising and is in good agreement with previous studies which demonstrated the virucidal effect of NO <ref type="bibr" target="#b8">(Croen, 1993;</ref><ref type="bibr" target="#b0">Akaike and Maeda, 2000)</ref>. The JNK signaling cascade is also a crucial effector of the antiviral immune response in influenza virus <ref type="bibr" target="#b18">(Hrincius et al., 2010)</ref>, but there are no data in favor of a cytoprotective effect against HSV-1 or EV71. The lack of a positive correlation between BR concentrations and JNK phosphorylation ( <ref type="figure" target="#fig_0">Figure 5A</ref>, in particular the 55-KDa isoform) could be explained keeping in mind that the bile pigment was used within the range 1-10 μM. It is interesting to recall that higher concentrations of BR (50 μM) were necessary to clearly stimulate the phosphorylation of MAPK members including JNK <ref type="bibr" target="#b12">(Fernandes et al., 2007)</ref>. In addition, the lack of any significant effect of the JNK inhibitor SP600125 (data not shown) on HSV-1 and EV71 infectivity lends support to the hypothesis that this pathway is not so efficacious to prevent viral infection as NO production. The parallel antiviral activity of BR against HSV-1 and EV71, characterized by important differences in terms of virion structure, a DNA-containing core surrounded by an envelope in HSV-1 and a RNA-containing core within a capsid without envelope in EV71, suggests that BR acts directly on the virion particles or on nucleic acids. In this light, some studies reported on a toxic effect of BR, in the presence of transition metals, on nucleic acids <ref type="bibr" target="#b1">(Asad et al., 1999)</ref>. Furthermore, the lack of direct antiviral activity of BV on HHV-6 and HSV-1 <ref type="bibr" target="#b33">(Nakagami et al., 1992)</ref> vis-à-vis with the efficient antiviral effect of BR against HSV-1 and EV71, implies an important role of the C-10, in analogy with previous results. The absence of double bonds at the γ-bridge (which includes C-10) stabilizes the structure of BR and increases its liposolubility with respect to BV. Moreover, the C-10 can undergo redox modifications under conditions of oxidative stress <ref type="bibr" target="#b40">(Stocker et al., 1987a;</ref><ref type="bibr" target="#b2">Baranano et al., 2002)</ref>. According to this hypothesis, free radicals could oxidize protein-bound BR at the C-10 generating BV which, in turn, is quickly reduced back to BR by the ubiquitous BVR <ref type="bibr" target="#b2">(Baranano et al., 2002)</ref>. However, this hypothesis is still debated in the scientific community <ref type="bibr" target="#b24">(Maghzal et al., 2009)</ref>, but it cannot be excluded to explain the antiviral effect of BR toward both HSV-1 and EV71.</p><p>In conclusion, the results in this paper provide the first evidence, to our knowledge, of a virucidal effect of BR against HSV-1 and EV71. The implication of these results for the development of new antiviral drugs designed to modulate the HO/BVR system are profound and research on these subjects is ongoing in our laboratories.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 5 |</head><label>5</label><figDesc>Effect of bilirubin (BR) on cellular expression of the c-JunN-terminal kinase (JNK) and nitric oxide (NO) production. Hep-2 and Vero cells were pre-incubated with BR (1-10 μM) for 2 h. At the end of incubation, BR was removed, the Hep-2 cells lysed and assayed for JNK phosphorylation by Western Blot (A) as described under the Section "Materials and Methods." α-tubulin was used as housekeeping gene to verify protein equal loading. On the contrary, Vero cells were assayed for NO production by using the fluorescent probe DAF-FM-diacetate [DAF-FM-DA, (B)] as described under the Section "Materials and Methods." (A) Shows a representative gel. In (B), data are expressed as DAF-FM-DA fluorescence arbitrary units (A.U), mean ± SEM of six individual samples per group. *P &lt; 0.05 versus control (C).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 6 |</head><label>6</label><figDesc>Effect of bilirubin (BR) plus the nitric oxide synthase inhibitor L-NG-monomethyl arginine citrate (L-NMMA) on herpes simplex virus type</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 2</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 3</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 4</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 5</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 6</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">March 2012 | Volume 3 | Article 36 | 7</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>The Authors want to thank Mrs. Simona Galuppi, Franca Pedone, and Creola Rocchetti for the expert technical assistance. This work was supported by Fondi Ateneo to Cesare Mancuso.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest Statement:</head><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Nitric oxide and virus infection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Akaike</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Maeda</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2567.2000.00142.x</idno>
		<idno type="PMID">11106932</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2327086?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<title level="j" type="abbrev">Immunology</title>
		<idno type="ISSN">0019-2805</idno>
		<idno type="ISSNe">1365-2567</idno>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="300" to="308" />
			<date type="published" when="2000-11" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Bilirubin-Cu(II) complex degrades DNA</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Farhan</forename><surname>Asad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Saurabh</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aamir</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Hadi</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0304-4165(99)00075-6</idno>
		<idno type="PMID">10434037</idno>
		<idno type="PII">S0304-4165(99)00075-6</idno>
		<idno type="ark">ark:/67375/6H6-RVD49B3N-B</idno>
		<idno type="istexId">F5AEAFD8E7BE77D28D9F69C51E0117BFFFDF553A</idno>
	</analytic>
	<monogr>
		<title level="j">Biochimica et Biophysica Acta (BBA) - General Subjects</title>
		<title level="j" type="abbrev">Biochimica et Biophysica Acta (BBA) - General Subjects</title>
		<idno type="ISSN">0304-4165</idno>
		<imprint>
			<biblScope unit="volume">1428</biblScope>
			<biblScope unit="issue">2-3</biblScope>
			<biblScope unit="page" from="201" to="208" />
			<date type="published" when="1999-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Biliverdin reductase: A major physiologic cytoprotectant</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Baranano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Ferris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Snyder</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.252626999</idno>
		<idno type="PMID">12456881</idno>
		<idno type="PMCID">PMC138570</idno>
		<ptr type="open-access" target="http://www.pnas.org/content/99/25/16093.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
		<idno type="ISSN">0027-8424</idno>
		<idno type="ISSNe">1091-6490</idno>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="16093" to="16098" />
			<date type="published" when="2002-11-27" />
			<publisher>Proceedings of the National Academy of Sciences</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Studies of bilirubin kinetics in normal adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">D</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">B</forename><surname>Howe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">R</forename><surname>Bloomer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nathaniel</forename><forename type="middle">I</forename><surname>Berlin</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci106184</idno>
		<idno type="PMID">5824077</idno>
		<idno type="PMCID">PMC297471</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/106184/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2176" to="2190" />
			<date type="published" when="1969-11-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Interpretation of plasma bilirubin levels based on studies with radioactive bilirubin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Bloomer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">D</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">B</forename><surname>Howe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">I</forename><surname>Berlin</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.218.2.216</idno>
		<idno type="PMID">4938053</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA: The Journal of the American Medical Association</title>
		<idno type="ISSN">0098-7484</idno>
		<idno type="ISSNe">1538-3598</idno>
		<imprint>
			<biblScope unit="volume">218</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="216" to="220" />
			<date type="published" when="1971-10-11" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Bogdan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Röllinghoff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><surname>Diefenbach</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0952-7915(99)00052-7</idno>
		<idno type="PMID">10679404</idno>
		<idno type="PII">S0952-7915(99)00052-7</idno>
		<idno type="ark">ark:/67375/6H6-9S3K6LCL-Q</idno>
		<idno type="istexId">7095CAB390CC30E47AB1C7EE924BB533E6213259</idno>
	</analytic>
	<monogr>
		<title level="j">Current Opinion in Immunology</title>
		<title level="j" type="abbrev">Current Opinion in Immunology</title>
		<idno type="ISSN">0952-7915</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="64" to="76" />
			<date type="published" when="2000-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Endogenous Carbon Monoxide Production</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">F</forename><surname>Coburn</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm197001222820407</idno>
		<idno type="PMID">4902834</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="207" to="209" />
			<date type="published" when="1970-01-22" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Herpes Simplex Virus Replication: Roles of Viral Proteins and Nucleoporins in Capsid-Nucleus Attachment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Newcomb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Brown</surname></persName>
		</author>
		<idno type="DOI">10.1128/jvi.01139-08</idno>
		<idno type="PMID">19073727</idno>
		<idno type="PMCID">PMC2643781</idno>
		<ptr type="open-access" target="https://jvi.asm.org/content/83/4/1660.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Virology</title>
		<title level="j" type="abbrev">Journal of Virology</title>
		<idno type="ISSN">0022-538X</idno>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1660" to="1668" />
			<date type="published" when="2008-12-10" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">D</forename><surname>Croen</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci116479</idno>
		<idno type="PMID">8390481</idno>
		<idno type="PMCID">PMC443304</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/116479/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2446" to="2452" />
			<date type="published" when="1993-06-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Carbon Monoxide-releasing Antibacterial Molecules Target Respiration and Global Transcriptional Regulators</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kelly</forename><forename type="middle">S</forename><surname>Davidge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guido</forename><surname>Sanguinetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chu</forename><forename type="middle">Hoi</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">G</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cameron</forename><forename type="middle">W</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claire</forename><forename type="middle">E</forename><surname>Monk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brian</forename><forename type="middle">E</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberto</forename><surname>Motterlini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">K</forename><surname>Poole</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m808210200</idno>
		<idno type="PMID">19091747</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/284/7/4516.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="4516" to="4524" />
			<date type="published" when="2008-12-17" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Differential Antibacterial Activity Against Pseudomonas aeruginosa by Carbon Monoxide-Releasing Molecules</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mathieu</forename><surname>Desmard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberta</forename><surname>Foresti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Didier</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maylis</forename><surname>Dagouassat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alain</forename><surname>Berdeaux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erick</forename><surname>Denamur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sian</forename><forename type="middle">H</forename><surname>Crook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brian</forename><forename type="middle">E</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Scapens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><surname>Montravers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jorge</forename><surname>Boczkowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberto</forename><surname>Motterlini</surname></persName>
		</author>
		<idno type="DOI">10.1089/ars.2011.3959</idno>
		<idno type="PMID">21864022</idno>
		<ptr type="open-access" target="https://www.hal.inserm.fr/inserm-00656413/file/ars.2011.pdf" />
	</analytic>
	<monogr>
		<title level="j">Antioxidants &amp; Redox Signaling</title>
		<title level="j" type="abbrev">Antioxidants &amp; Redox Signaling</title>
		<idno type="ISSN">1523-0864</idno>
		<idno type="ISSNe">1557-7716</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="163" />
			<date type="published" when="2012-01-15" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Antimicrobial reactive oxygen and nitrogen species: concepts and controversies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ferric</forename><forename type="middle">C</forename><surname>Fang</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrmicro1004</idno>
		<idno type="PMID">15378046</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Microbiology</title>
		<title level="j" type="abbrev">Nat Rev Micro</title>
		<idno type="ISSN">1740-1526</idno>
		<idno type="ISSNe">1740-1534</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="820" to="832" />
			<date type="published" when="2004-10" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">MAPKs are key players in mediating cytokine release and cell death induced by unconjugated bilirubin in cultured rat cortical astrocytes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Adelaide</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ana</forename><forename type="middle">S</forename><surname>Falcão</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rui</forename><forename type="middle">F M</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">A</forename><surname>Brito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dora</forename><surname>Brites</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1460-9568.2007.05340.x</idno>
		<idno type="PMID">17331202</idno>
		<idno type="ark">ark:/67375/WNG-ZJHRXBWD-Z</idno>
		<idno type="istexId">40C26477C13C2451473FA1BBF3E42DA8C4B804A4</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Neuroscience</title>
		<idno type="ISSN">0953-816X</idno>
		<idno type="ISSNe">1460-9568</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1058" to="1068" />
			<date type="published" when="2007-02-26" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lea</forename><surname>Fialkow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yingchun</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><forename type="middle">P</forename><surname>Downey</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.freeradbiomed.2006.09.030</idno>
		<idno type="PMID">17189821</idno>
	</analytic>
	<monogr>
		<title level="j">Free Radical Biology and Medicine</title>
		<title level="j" type="abbrev">Free Radical Biology and Medicine</title>
		<idno type="ISSN">0891-5849</idno>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="164" />
			<date type="published" when="2007-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Gilbert&apos;s syndrome: an overview for clinical biochemists</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">M</forename><surname>Hirschfield</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">J</forename><surname>Alexander</surname></persName>
		</author>
		<idno type="DOI">10.1258/000456306778520034</idno>
		<idno type="PMID">17022875</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Clinical Biochemistry</title>
		<title level="j" type="abbrev">ann clin biochem</title>
		<idno type="ISSN">0004-5632</idno>
		<idno type="ISSNe">0000-0000</idno>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="340" to="343" />
			<date type="published" when="2006-09-01" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann. Clin. Biochem</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="340" to="343" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Serum Bilirubin and Risk of Respiratory Disease and Death</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><forename type="middle">J</forename><surname>Horsfall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Rait</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Walters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Swallow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Nazareth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Petersen</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2011.124</idno>
		<idno type="PMID">21325185</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jama/articlepdf/894260/joc15008_691_697.pdf" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<title level="j" type="abbrev">JAMA</title>
		<idno type="ISSN">0098-7484</idno>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">691</biblScope>
			<date type="published" when="2011-02-16" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Hong</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying</forename><surname>Shan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Yu</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">W</forename><surname>Lambrecht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Herbert</forename><forename type="middle">L</forename><surname>Bonkovsky</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.15.4499</idno>
		<idno type="PMID">19777608</idno>
		<idno type="PMCID">PMC2751994</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Gastroenterology</title>
		<title level="j" type="abbrev">WJG</title>
		<idno type="ISSN">1007-9327</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">36</biblScope>
			<biblScope unit="page">4499</biblScope>
			<date type="published" when="2009" />
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CRK adaptor protein expression is required for efficient replication of avian influenza A viruses and controls JNK-mediated apoptotic responses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eike</forename><forename type="middle">R</forename><surname>Hrincius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Viktor</forename><surname>Wixler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thorsten</forename><surname>Wolff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephan</forename><surname>Ludwig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christina</forename><surname>Ehrhardt</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1462-5822.2010.01436.x</idno>
		<idno type="PMID">20088952</idno>
		<ptr type="open-access" target="https://edoc.rki.de/bitstream/176904/792/1/26CSqkglwVXY.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cellular Microbiology</title>
		<idno type="ISSN">1462-5814</idno>
		<idno type="ISSNe">1462-5822</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="831" to="843" />
			<date type="published" when="2010-01-20" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H-C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T-C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K-J</forename><surname>Yen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-R</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Null-</forename><forename type="middle">A</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-P</forename><surname>Tseng</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dkp502</idno>
		<idno type="PMID">20089540</idno>
		<idno type="ark">ark:/67375/HXZ-NW4FL4V4-G</idno>
		<idno type="istexId">8FFF823E2AF2FABBC6EB1C5F182A322DD7617FB5</idno>
		<ptr type="open-access" target="https://academic.oup.com/jac/article-pdf/65/4/676/2458524/dkp502.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Antimicrobial Chemotherapy</title>
		<title level="j" type="abbrev">Journal of Antimicrobial Chemotherapy</title>
		<idno type="ISSN">0305-7453</idno>
		<idno type="ISSNe">1460-2091</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="676" to="683" />
			<date type="published" when="2010-01-20" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Interaction of bilirubin and biliverdin with reactive nitrogen species</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harparkash</forename><surname>Kaur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><forename type="middle">N</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><forename type="middle">J</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Naughton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberta</forename><surname>Foresti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberto</forename><surname>Motterlini</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0014-5793(03)00420-4</idno>
		<idno type="PMID">12753916</idno>
	</analytic>
	<monogr>
		<title level="j">FEBS Letters</title>
		<idno type="ISSN">0014-5793</idno>
		<imprint>
			<biblScope unit="volume">543</biblScope>
			<biblScope unit="issue">1-3</biblScope>
			<biblScope unit="page" from="113" to="119" />
			<date type="published" when="2003-04-30" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Detection of enteroviruses from clinical specimens by spin amplification shell vial culture and monoclonal antibody assay</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Klespies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Cebula</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Galehouse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Microbiol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1465" to="1467" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Nystatin-induced nitric oxide production in mouse macrophage-like cell line RAW264.7</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naoki</forename><surname>Koide</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshikazu</forename><surname>Naiki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akiko</forename><surname>Morikawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gantsetseg</forename><surname>Tumurkhuu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jargalsaikhan</forename><surname>Dagvadorj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abu</forename><forename type="middle">Shadat Mohammod</forename><surname>Noman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Imtiaz</forename><surname>Iftekar-E-Khuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takayuki</forename><surname>Komatsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tomoaki</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takashi</forename><surname>Yokochi</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1348-0421.2009.00118.x</idno>
		<idno type="PMID">19457171</idno>
		<idno type="ark">ark:/67375/WNG-X9B4VNZW-P</idno>
		<idno type="istexId">3B9B2C7A90D4009E93F117014824F644BFAAFED2</idno>
	</analytic>
	<monogr>
		<title level="j">Microbiology and Immunology</title>
		<idno type="ISSN">0385-5600</idno>
		<idno type="ISSNe">1348-0421</idno>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="295" to="300" />
			<date type="published" when="2009-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabeth</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Walid</forename><forename type="middle">Hamdy</forename><surname>El-Tantawy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><surname>Ocker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><surname>Bartenschlager</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Volker</forename><surname>Lohmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Said</forename><surname>Hashemolhosseini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gisa</forename><surname>Tiegs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gabriele</forename><surname>Sass</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.23339</idno>
		<idno type="PMID">20044809</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="398" to="404" />
			<date type="published" when="2009-09-29" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Limited Role for the Bilirubin-Biliverdin Redox Amplification Cycle in the Cellular Antioxidant Protection by Biliverdin Reductase</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ghassan</forename><forename type="middle">J</forename><surname>Maghzal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Meng-Choo</forename><surname>Leck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emma</forename><surname>Collinson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheng</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roland</forename><surname>Stocker</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m109.037119</idno>
		<idno type="PMID">19690164</idno>
		<idno type="PMCID">PMC2785555</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/284/43/29251.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="issue">43</biblScope>
			<biblScope unit="page" from="29251" to="29259" />
			<date type="published" when="2009-08-18" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">THE HEME OXYGENASE SYSTEM:A Regulator of Second Messenger Gases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mahin</forename><forename type="middle">D</forename><surname>Maines</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev.pharmtox.37.1.517</idno>
		<idno type="PMID">9131263</idno>
	</analytic>
	<monogr>
		<title level="j">Annual Review of Pharmacology and Toxicology</title>
		<title level="j" type="abbrev">Annu. Rev. Pharmacol. Toxicol.</title>
		<idno type="ISSN">0362-1642</idno>
		<idno type="ISSNe">1545-4304</idno>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="517" to="554" />
			<date type="published" when="1997-04" />
			<publisher>Annual Reviews</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">New Insights into Biliverdin Reductase Functions: Linking Heme Metabolism to Cell Signaling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mahin</forename><forename type="middle">D</forename><surname>Maines</surname></persName>
		</author>
		<idno type="DOI">10.1152/physiol.00029.2005</idno>
		<idno type="PMID">16287987</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/ffd1/ded764b2275f8f91d891d5085391a927ed16.pdf" />
	</analytic>
	<monogr>
		<title level="j">Physiology</title>
		<title level="j" type="abbrev">Physiology</title>
		<idno type="ISSN">1548-9213</idno>
		<idno type="ISSNe">1548-9221</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="382" to="389" />
			<date type="published" when="2005-12" />
			<publisher>American Physiological Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Mancuso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Barone</surname></persName>
		</author>
		<idno type="DOI">10.2174/138920009789375405</idno>
		<idno type="PMID">19702533</idno>
	</analytic>
	<monogr>
		<title level="j">Current Drug Metabolism</title>
		<title level="j" type="abbrev">CDM</title>
		<idno type="ISSN">1389-2002</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="579" to="594" />
			<date type="published" when="2009-07-01" />
			<publisher>Bentham Science Publishers Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Albumin-Bound Bilirubin Interacts with Nitric Oxide by a Redox Mechanism</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cesare</forename><surname>Mancuso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessia</forename><surname>Bonsignore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caterina</forename><surname>Capone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Enrico</forename><forename type="middle">Di</forename><surname>Stasio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovambattista</forename><surname>Pani</surname></persName>
		</author>
		<idno type="DOI">10.1089/ars.2006.8.487</idno>
		<idno type="PMID">16677092</idno>
	</analytic>
	<monogr>
		<title level="j">Antioxidants &amp; Redox Signaling</title>
		<title level="j" type="abbrev">Antioxidants &amp; Redox Signaling</title>
		<idno type="ISSN">1523-0864</idno>
		<idno type="ISSNe">1557-7716</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3-4</biblScope>
			<biblScope unit="page" from="487" to="494" />
			<date type="published" when="2006-03" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cesare</forename><surname>Mancuso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovambattista</forename><surname>Pani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vittorio</forename><surname>Calabrese</surname></persName>
		</author>
		<idno type="DOI">10.1179/135100006x154978</idno>
		<idno type="PMID">17132269</idno>
		<ptr type="open-access" target="https://www.tandfonline.com/doi/pdf/10.1179/135100006X154978?needAccess=true" />
	</analytic>
	<monogr>
		<title level="j">Redox Report</title>
		<title level="j" type="abbrev">Redox Report</title>
		<idno type="ISSN">1351-0002</idno>
		<idno type="ISSNe">1743-2928</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="207" to="213" />
			<date type="published" when="2006-10" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Bilirubin as an endogenous modulator of neurotrophin redox signaling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cesare</forename><surname>Mancuso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caterina</forename><surname>Capone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sofia</forename><forename type="middle">Chiatamone</forename><surname>Ranieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Fusco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vittorio</forename><surname>Calabrese</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">Luisa</forename><surname>Eboli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><surname>Preziosi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tommaso</forename><surname>Galeotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovambattista</forename><surname>Pani</surname></persName>
		</author>
		<idno type="DOI">10.1002/jnr.21665</idno>
		<idno type="PMID">18338802</idno>
		<idno type="ark">ark:/67375/WNG-6X98B8ZZ-6</idno>
		<idno type="istexId">144816DEBF17C0F0E23ED36C54BC79E2184994F9</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Neuroscience Research</title>
		<title level="j" type="abbrev">J. Neurosci. Res.</title>
		<idno type="ISSN">0360-4012</idno>
		<idno type="ISSNe">1097-4547</idno>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2235" to="2249" />
			<date type="published" when="2008-08-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Bilirubin Is an Effective Antioxidant of Peroxynitrite-Mediated Protein Oxidation in Human Blood Plasma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maurizio</forename><surname>Minetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cinzia</forename><surname>Mallozzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Maria Michela</forename><surname>Di Stasi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donatella</forename><surname>Pietraforte</surname></persName>
		</author>
		<idno type="DOI">10.1006/abbi.1998.0584</idno>
		<idno type="PMID">9587403</idno>
		<idno type="PII">S0003-9861(98)90584-7</idno>
		<idno type="ark">ark:/67375/6H6-4GVMMR2G-G</idno>
		<idno type="istexId">DBD7E6B40FFB5E9F62CE34DDD3A4ED94177672D0</idno>
	</analytic>
	<monogr>
		<title level="j">Archives of Biochemistry and Biophysics</title>
		<title level="j" type="abbrev">Archives of Biochemistry and Biophysics</title>
		<idno type="ISSN">0003-9861</idno>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="165" to="174" />
			<date type="published" when="1998-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">In vitro Anti-human Immunodeficiency Virus Type 1 Activity of Biliverdin, a Bile Pigment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haruyo</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toru</forename><surname>Otake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Motoko</forename><surname>Morimoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noboru</forename><surname>Ueba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nobuharu</forename><surname>Kunita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tatsuyoshi</forename><surname>Nakagami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Non</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shiro</forename><surname>Taji</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1349-7006.1991.tb02698.x</idno>
		<idno type="PMID">1715337</idno>
		<idno type="PMCID">PMC5918533</idno>
	</analytic>
	<monogr>
		<title level="j">Japanese Journal of Cancer Research</title>
		<idno type="ISSN">0910-5050</idno>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="755" to="757" />
			<date type="published" when="1991-07" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">Antiviral activity of a bile pigment, biliverdin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Nakagami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Taji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yamanishi</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename></persName>
		</author>
		<imprint>
			<date type="published" when="1992" />
		</imprint>
	</monogr>
	<note>against human herpesvirus 6 (HHV-</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">in vitro. Microbiol. Immunol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="381" to="390" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Exploring the antimicrobial action of a carbon monoxide-releasing compound through whole-genome transcription profiling of Escherichia coli</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Nobre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Al-Shahrour</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Dopazo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Saraiva</surname></persName>
		</author>
		<idno type="DOI">10.1099/mic.0.023911-0</idno>
		<idno type="PMID">19246752</idno>
		<ptr type="open-access" target="http://mic.microbiologyresearch.org/deliver/fulltext/micro/155/3/813.pdf?itemId=/content/journal/micro/10.1099/mic.0.023911-0&amp;mimeType=pdf&amp;isFastTrackArticle=" />
	</analytic>
	<monogr>
		<title level="j">Microbiology</title>
		<title level="j" type="abbrev">Microbiology</title>
		<idno type="ISSN">1350-0872</idno>
		<idno type="ISSNe">1465-2080</idno>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="813" to="824" />
			<date type="published" when="2009-03-01" />
			<publisher>Microbiology Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Antimicrobial Action of Carbon Monoxide-Releasing Compounds</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Nobre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Seixas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Romao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Saraiva</surname></persName>
		</author>
		<idno type="DOI">10.1128/aac.00802-07</idno>
		<idno type="PMID">17923486</idno>
		<idno type="PMCID">PMC2167974</idno>
		<ptr type="open-access" target="https://aac.asm.org/content/aac/51/12/4303.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Antimicrobial Agents and Chemotherapy</title>
		<title level="j" type="abbrev">Antimicrobial Agents and Chemotherapy</title>
		<idno type="ISSN">0066-4804</idno>
		<idno type="ISSNe">1098-6596</idno>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4303" to="4307" />
			<date type="published" when="2007-10-08" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Inhibition of Herpesvirus Replication by 5-Substituted 4&apos;-Thiopyrimidine Nucleosides</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">N</forename><surname>Prichard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Quenelle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Hartline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Harden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Frederick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Daily</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Whitley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Tiwari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Maddry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Secrist</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">R</forename><surname>Kern</surname></persName>
		</author>
		<idno type="DOI">10.1128/aac.00417-09</idno>
		<idno type="PMID">19770274</idno>
		<idno type="PMCID">PMC2786333</idno>
		<ptr type="open-access" target="https://aac.asm.org/content/53/12/5251.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Antimicrobial Agents and Chemotherapy</title>
		<title level="j" type="abbrev">Antimicrobial Agents and Chemotherapy</title>
		<idno type="ISSN">0066-4804</idno>
		<idno type="ISSNe">1098-6596</idno>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="5251" to="5258" />
			<date type="published" when="2009-09-21" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Enterovirus infection and activation of human umbilical vein endothelial cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salla</forename><surname>Saijets</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Petri</forename><surname>Ylipaasto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Outi</forename><surname>Vaarala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapani</forename><surname>Hovi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Merja</forename><surname>Roivainen</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmv.10413</idno>
		<idno type="PMID">12767007</idno>
		<idno type="ark">ark:/67375/WNG-PHRV1N15-L</idno>
		<idno type="istexId">0E1941A998F2162E186D901986B94DFFFF89F0B2</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medical Virology</title>
		<title level="j" type="abbrev">J. Med. Virol.</title>
		<idno type="ISSN">0146-6615</idno>
		<idno type="ISSNe">1096-9071</idno>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="430" to="439" />
			<date type="published" when="2003-05-06" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Herpes Simplex Viremia: Report of Eight Pediatric Cases and Review of the Literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">R</forename><surname>Stanberry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Floyd-Reising</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Connelly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J R</forename><surname>Gilchrist</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">G</forename><surname>Myers</surname></persName>
		</author>
		<idno type="DOI">10.1093/clinids/18.3.401</idno>
		<idno type="PMID">8011823</idno>
		<idno type="ark">ark:/67375/HXZ-VQN21LS9-W</idno>
		<idno type="istexId">FA371FD965642350C74B879937CAC3A1A2A8EE41</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Infectious Diseases</title>
		<title level="j" type="abbrev">Clinical Infectious Diseases</title>
		<idno type="ISSN">1058-4838</idno>
		<idno type="ISSNe">1537-6591</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="401" to="407" />
			<date type="published" when="1994-03-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Antioxidant activity of albumin-bound bilirubin.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Stocker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">N</forename><surname>Glazer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Ames</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.84.16.5918</idno>
		<idno type="PMID">3475708</idno>
		<idno type="PMCID">PMC298974</idno>
		<ptr type="open-access" target="http://www.pnas.org/content/84/16/5918.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
		<idno type="ISSN">0027-8424</idno>
		<idno type="ISSNe">1091-6490</idno>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="5918" to="5922" />
			<date type="published" when="1987-08-01" />
			<publisher>Proceedings of the National Academy of Sciences</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Bilirubin is an antioxidant of possible physiological importance</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Stocker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Mcdonagh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">N</forename><surname>Glazer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Ames</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.3029864</idno>
		<idno type="PMID">3029864</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<title level="j" type="abbrev">Science</title>
		<idno type="ISSN">0036-8075</idno>
		<idno type="ISSNe">1095-9203</idno>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="issue">4792</biblScope>
			<biblScope unit="page" from="1043" to="1046" />
			<date type="published" when="1987-02-27" />
			<publisher>American Association for the Advancement of Science (AAAS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Requirements for Nitric Oxide Generation from Isoniazid Activation In Vitro and Inhibition of Mycobacterial Respiration In Vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Timmins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Master</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Rusnak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Deretic</surname></persName>
		</author>
		<idno type="DOI">10.1128/jb.186.16.5427-5431.2004</idno>
		<idno type="PMID">15292144</idno>
		<idno type="PMCID">PMC490879</idno>
		<ptr type="open-access" target="https://jb.asm.org/content/jb/186/16/5427.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Bacteriology</title>
		<title level="j" type="abbrev">Journal of Bacteriology</title>
		<idno type="ISSN">0021-9193</idno>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="5427" to="5431" />
			<date type="published" when="2004-08-03" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Enterovirus 71 induces integrin β1/EGFR-Rac1-dependent oxidative stress in SK-N-SH cells: Role of HO-1/CO in viral replication</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Hsuan</forename><surname>Tung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hsi-Lung</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chuen-Mao</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcp.22677</idno>
		<idno type="PMID">21321939</idno>
		<idno type="ark">ark:/67375/WNG-HX316MTX-R</idno>
		<idno type="istexId">A46E62F00466C0E11A67E4F0474250226EF7A3D9</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Cellular Physiology</title>
		<title level="j" type="abbrev">J. Cell. Physiol.</title>
		<idno type="ISSN">0021-9541</idno>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3316" to="3329" />
			<date type="published" when="2011-09-23" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Carbon monoxide: a putative neural messenger</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Glatt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">V</forename><surname>Ronnett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Snyder</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.7678352</idno>
		<idno type="PMID">7678352</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<title level="j" type="abbrev">Science</title>
		<idno type="ISSN">0036-8075</idno>
		<idno type="ISSNe">1095-9203</idno>
		<imprint>
			<biblScope unit="volume">259</biblScope>
			<biblScope unit="issue">5093</biblScope>
			<biblScope unit="page" from="381" to="384" />
			<date type="published" when="1993-01-15" />
			<publisher>American Association for the Advancement of Science (AAAS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Libor</forename><surname>Vı́tek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Milan</forename><surname>Jirsa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie</forename><surname>Brodanová</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Milan</forename><surname>Kaláb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zdeněk</forename><surname>Mareček</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vilém</forename><surname>Danzig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ladislav</forename><surname>Novotný</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Petr</forename><surname>Kotal</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0021-9150(01)00601-3</idno>
		<idno type="PMID">11849670</idno>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<title level="j" type="abbrev">Atherosclerosis</title>
		<idno type="ISSN">0021-9150</idno>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="449" to="456" />
			<date type="published" when="2002-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels</title>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="page" from="449" to="456" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wang</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename></persName>
		</author>
		<idno type="DOI">10.1124/pr.57.4.3</idno>
		<idno type="PMID">16382109</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacological Reviews</title>
		<title level="j" type="abbrev">Pharmacological Reviews</title>
		<idno type="ISSN">0031-6997</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="585" to="630" />
			<date type="published" when="2005-12-01" />
			<publisher>American Society for Pharmacology &amp; Experimental Therapeutics (ASPET)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhaowen</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne</forename><forename type="middle">T</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruce</forename><forename type="middle">A</forename><surname>Luxon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyle</forename><forename type="middle">E</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Meleah</forename><surname>Mathahs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sarmistha</forename><surname>Bandyopadhyay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anton</forename><forename type="middle">P</forename><surname>Mccaffrey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Warren</forename><forename type="middle">N</forename><surname>Schmidt</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.23921</idno>
		<idno type="PMID">21105106</idno>
		<idno type="PMCID">PMC3058505</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3058505?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1897" to="1905" />
			<date type="published" when="2010-11-23" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?</title>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1897" to="1905" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
